AbbVie
As on 31 Dec, 2025 | 02:29 IST
| Open | 230.77 |
| Previous Close | 230.84 |
| Beta | 0.16 |
| High | 231.21 |
| Low | 228.62 |
| TTM EPS See historical trend | 9.45(-12.09% YoY) |
| 52 Week High | 244.80 |
| 52 Week Low | 164.59 |
| TTM PE See historical trend | 24.31(High PE) |
| Mkt. Cap ($ Billion) | 405.93 |
| Dividend Yield | 3.49 |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 229.47 |
| 10 | 227.24 |
| 20 | 226.28 |
| 50 | 226.78 |
| 100 | 221.6 |
| 200 | 205.6 |
Returns
| 1 Week | 0.40% | |
| 1 Month | 0.88% | |
| 3 Months | -0.79% | |
| YTD | 29.26% | |
| 1 Year | 30.32% | |
| 3 Years | 42.14% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 1,079.80 | 0.10 | 1,027.13 | 49.13 | 21.99 | 0.74 | 1,111.99/623.99 | 0.54 | Very Bullish |
| J&J | 206.95 | -0.29 | 498.70 | 19.94 | 10.38 | 2.83 | 215.04/141.30 | 0.13 | Bullish |
| AbbVie | 229.74 | -0.48 | 405.93 | 24.31 | 9.45 | 3.49 | 244.80/164.59 | 0.88 | Very Bullish |
| Merck | 106.07 | -0.52 | 268.69 | 12.26 | 8.65 | 3.86 | 107.59/73.35 | 1.41 | Very Bullish |
| Abbott | 125.78 | 0.97 | 218.21 | 25.21 | 4.99 | 1.76 | 141.07/110.89 | -2.40 | Bearish |
Market news
- Dow, S&P 500 close at record highs as Santa rally startsDecember 25, 2025 8:04 AM
- Stocks rise with tech boost, yen weakens after Japan rate hikeDecember 20, 2025 12:20 PM
- Wall Street ends lower; fears of AI bubble and inflation send investors awayDecember 13, 2025 9:01 AM
- Wall Street closes with slight gains as data keeps Fed cut expectations on trackDecember 6, 2025 8:34 AM
About the company
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.